Not currently recruiting at UCSF
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Nina Shah
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Nina Shah
Dr. Nina Shah is a hematologist who specializes in the treatment of multiple myeloma, a type of cancer affecting the blood marrow. She treats patients at the Hematology and Blood Marrow and Transplant Clinic. Nina received a bachelor’s degree in cognitive neuroscience at Harvard University, followed by a medical degree from New York University School of Medicine.
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Poseida Therapeutics, Inc.
- ID
- NCT04960579
- Phase
- Phase 1 Multiple Myeloma Research Study
- Study Type
- Interventional
- Participants
- Expecting 135 study participants
- Last Updated